Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
about
Emerging Threats in Antifungal-Resistant Fungal PathogensIntegrated therapy for HIV and cryptococcosisAntifungal resistance in pathogenic fungiAntifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis.Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxisCorrespondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.Antifungal susceptibility testing: practical aspects and current challenges.Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care centerIn vitro antifungal susceptibility testing.In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis.Antifungal use in HIV infection.Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosisHas antifungal susceptibility testing come of age?Cryptococcosis in a bottlenose dolphin (Tursiops truncatus) caused by Cryptococcus neoformans var. gattiiTrends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008.Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazoleIncreased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients.Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.Diagnosis and Management of Cryptococcal Relapse.Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.Fluconazole resistance in cryptococcal disease: emerging or intrinsic?The evolving role of antifungal susceptibility testing.Physiological Differences in Cryptococcus neoformans Strains In Vitro versus In Vivo and Their Effects on Antifungal SusceptibilityUse of voriconazole in non-meningeal cryptococcosis.Fluconazole Non-susceptible Cryptococcus neoformans, Relapsing/Refractory Cryptococcosis and Long-term Use of Liposomal Amphotericin B in an AIDS Patient.Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States.In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.[First description of phenotypic profile and in vitro drug susceptibility of Cryptococcus spp yeast isolated from HIV-positive and HIV-negative patients in State of Mato Grosso].First molecular typing of cryptococcemia-causing cryptococcus in central-west Brazil.Antifungal susceptibility, enzymatic activity, PCR-fingerprinting and ITS sequencing of environmental Cryptococcus laurentii isolates from Uberaba, Minas Gerais, Brazil.Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.
P2860
Q26750816-21586E74-F884-42A6-8DF0-0851393F9680Q28077707-66CA204E-5DF9-4902-8C23-A0BB036883FDQ28208165-977DFE73-07A2-46CF-9F30-5A636B8E96AAQ30981454-518CAB8F-EA68-48ED-8316-674E190FD2BFQ33710112-C86E417C-05B5-4312-BBA4-005D291FC269Q33859215-0BCB8EAE-6937-4B03-9CC3-DF891C9FD077Q33892987-E331E940-81E9-48AB-A2AE-C121B12A112EQ33938166-D2078F67-6FDB-4FD8-A481-C3765C35B684Q33975757-2F2DE64E-5722-420E-96AF-F800CFBEFC99Q33983318-B567D21E-1770-4CA5-BF59-05EFE5A8A30BQ34020746-9FC637C9-4E3C-4FCF-9BEC-3B9145A39F00Q34058322-36EC6C10-AB0C-4413-876F-47E0B4045F97Q34335217-2572F582-DCB4-490B-BB30-CA809F91596CQ34489508-12FC9845-262E-45E8-B866-123F1F499C0BQ34518388-7E3B71C7-1320-468D-8995-CA1076318780Q34519212-8B195D6C-1619-4687-82D4-8194E058FE17Q34721673-E4F55506-1EF7-463F-B71F-5F906D9C2C2AQ34923038-E4F59231-10B0-41F4-BF76-6C466FE7B82DQ34945782-F265CF82-C21E-4540-994A-EE0DFA1517B9Q35004926-C1C6E857-8D28-4F88-B9AB-D9B80EC35052Q35552662-C6B0A789-782F-4169-AB7C-F3F021631393Q36290696-F4F5FCAB-68D5-4F49-A9F7-A02BFBE707D1Q36364064-CAFFFB27-4B26-4833-9071-14D922941737Q37026726-FE15B2C5-6F65-40B3-A703-AFB15992077AQ37091636-10F777A0-4B9A-4F75-A97C-8DFC91A6FCA9Q37247728-4A7F72D1-9AD2-48EC-8B9F-6ACE0C598E6AQ37409922-50AEBF22-AA96-43A1-A944-601F5800C70EQ37643602-B66BBB8C-4AC2-46F1-B833-92CCDAE27489Q38044487-C64C0AF6-A5D0-4CF1-8269-920322935A47Q38095809-29A91CC3-FD99-4FE1-AFCA-9816F0945AE6Q39061501-8F655BEB-6F36-40AE-ABEC-02B9416478ACQ39466434-CE31E694-DEC7-400C-8F09-F98281D4D55CQ40155503-18B983E2-5D4E-4F04-BF79-F4EC7F393468Q40796391-2593257B-2BC5-4A7E-86D1-699BC0710513Q42924504-21182554-EE8E-47A4-BF97-278CE96C4B32Q43111743-2CF9348D-E62A-4B7A-A3E8-9FE7BA647166Q43140037-0E8D569E-2757-41ED-9C44-C4B1560F638CQ44611332-C7548A41-AEA4-4BE7-927F-3D8C182C9C49Q44767335-47C46F2C-4620-4D76-B807-C9C01F2B6F17Q46421581-A64FFF1C-B610-4FEC-A4C7-46A0F46940CE
P2860
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
@ast
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
@en
type
label
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
@ast
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
@en
prefLabel
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
@ast
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
@en
P2093
P2860
P1476
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection
@en
P2093
A Espinel-Ingroff
J Gomez-Mateos
L Steele-Moore
M J Gutiérrez
W J Holloway
P2860
P304
P356
10.1128/AAC.44.6.1544-1548.2000
P407
P577
2000-06-01T00:00:00Z